Telaprevir

Generic Name
Telaprevir
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C36H53N7O6
CAS Number
402957-28-2
Unique Ingredient Identifier
655M5O3W0U
Background

Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...

Indication

Telaprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .

Associated Conditions
Chronic Hepatitis C Genotype 1
Associated Therapies
-
Clinical Trials
Related News

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

First Posted Date
2011-01-12
Last Posted Date
2011-06-08
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
16
Registration Number
NCT01275599

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

First Posted Date
2010-11-16
Last Posted Date
2014-06-04
Lead Sponsor
Janssen Infectious Diseases BVBA
Target Recruit Count
744
Registration Number
NCT01241760

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

First Posted Date
2010-03-04
Last Posted Date
2020-09-30
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
152
Registration Number
NCT01080222

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

First Posted Date
2010-01-22
Last Posted Date
2013-05-08
Lead Sponsor
Janssen Infectious Diseases BVBA
Target Recruit Count
90
Registration Number
NCT01054573

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

First Posted Date
2009-12-23
Last Posted Date
2010-04-08
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
20
Registration Number
NCT01038167

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Phase 1
Completed
Conditions
Hepatitis C
Interventions
Drug: VCH-222
Drug: telaprevir
First Posted Date
2009-08-13
Last Posted Date
2010-01-07
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
30
Registration Number
NCT00958152

A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Telaprevir
Drug: Methadone
First Posted Date
2009-07-07
Last Posted Date
2012-12-03
Lead Sponsor
Tibotec BVBA
Target Recruit Count
18
Registration Number
NCT00933283

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Completed
Conditions
Hepatitis C
Interventions
Drug: telaprevir
First Posted Date
2009-06-09
Last Posted Date
2014-02-27
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
408
Registration Number
NCT00916474
Locations
🇺🇸

Maryland, Baltimore, Maryland, United States

🇺🇸

South Carolina, Columbia, South Carolina, United States

🇺🇸

Florida, Miami, Florida, United States

and more 17 locations

VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

Phase 1
Completed
Conditions
Hepatitis C
Kidney Diseases
First Posted Date
2009-05-18
Last Posted Date
2010-12-17
Lead Sponsor
Tibotec BVBA
Target Recruit Count
24
Registration Number
NCT00903773

Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

First Posted Date
2009-05-04
Last Posted Date
2015-03-20
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
15
Registration Number
NCT00892697
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy